Digital Pathology Finally Has FDA-Cleared AI. Why Hospital Adoption Is Still Spotty
Dr. Dereck Mush, MD, MBA
Paige
Creates AI-native digital pathology software to assist pathologists in diagnosing cancer.
What they do
Paige provides artificial intelligence applications and digital pathology tools to healthcare institutions. The software assists pathologists in detecting, characterizing, and grading breast and prostate cancers from tissue biopsies, aiming to improve diagnostic accuracy and efficiency in pathology laboratories.
The record
- Vertical
- Oncology
- Sub-segment
- AI digital pathology
- Product type
- Software as a medical device
- Stage
- Series C+
- Headquarters
- New York, United States
- Region
- North America
- Founded
- 2017
- Total funding
- $220M raised
Notable investors: Casdin Capital, Johnson & Johnson Innovation, KKR, Breyer Capital.
Also in Oncology
Related on The Signal
Dr. Dereck Mush, MD, MBA
Consolidating the Digital Slide: How Agilent's $270M Proscia Acquisition Signals the End of Standalone Pathology AI
Dr. Dereck Mush, MD, MBA
The Curative Adjuvant Checkpoint Pivot: How Genentech's ATOMIC Approval Redefines Early GI Oncology Economics and Reflex Testing Infrastructure
Dr. Dereck Mush, MD, MBA
Breaking the PMA Bottleneck: How FDA's Class II Reclassification Accelerates Precision Oncology
Dr. Dereck Mush, MD, MBA